Alimentary Pharmacology & Therapeutics

Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors
pp. 963-978(16)
Authors: Stedman, C. A. M.; Barclay, M. L.

Review article: the clinical influence of Helicobacter pylori in effective acid suppression—implications for the treatment of gastro-oesophageal reflux disease
pp. 979-990(12)
Authors: Martínek, J.; Kužela, L.; Špičák, J.; Vavrečka, A.

Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies
pp. 991-999(9)
Authors: Van Oijen, A. H. A. M.; Verbeek, A. L.; Jansen, J. B. M. J.; De Boer, W. A.

Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms
pp. 1001-1008(8)
Authors: Di Stefano, M.; Strocchi, A.; Malservisi, S.; Veneto, G.; Ferrieri, A.; Corazza, G. R.

Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy
pp. 1009-1014(6)
Authors: Cuffari, C.; Hunt, S.; Bayless, T. M.

Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease
pp. 1015-1022(8)
Authors: Ang, Y. S.; Mahmud, N.; White, B.; Byrne, M.; Kelly, A.; Lawler, M.; Mcdonald, G. S. A.; Smith, O. P.; Keeling, P. W. N.

Chemotactic properties of ICAM-1 and PECAM-1 on neutrophil granulocytes in ulcerative colitis: effects of prednisolone and mesalazine
pp. 1023-1031(9)
Authors: Vainer, B.; Nielsen, O. H.

Topical and intravenous administration of trefoil factors protect the gastric mucosa from ethanol-induced injury in the rat
pp. 1033-1040(8)
Authors: Mckenzie, C.; Thim, L.; Parsons, M. E.

Cisapride provides symptomatic relief in functional dyspepsia associated with gastric myoelectrical abnormality
pp. 1041-1047(7)
Authors: Chen, J. D. Z.; Ke, M. Y.; Lin, X. M.; Wang, Z.; Zhang, M.

Helicobacter pylori infection influences nocturnal gastric acid breakthrough
pp. 1049-1056(8)
Authors: Katsube, T.; Adachi, K.; Kawamura, A.; Amano, K.; Uchida, Y.; Watanabe, M.; Kinoshita, Y.

Pharmacodynamics and kinetics of omeprazole MUPS 20 mg and pantoprazole 40 mg during repeated oral administration in Helicobacter pylori-negative subjects
pp. 1057-1064(8)
Authors: Geus, W. P.; Mathôt, R. A. A.; Mulder, P. G. H.; Lamers, C. B. H. W.

Equally high efficacy of 4, 7 and 10-day triple therapies to eradicate Helicobacter pylori infection in patients with ulcer disease
pp. 1065-1070(6)
Authors: Hurenkamp, G. J. B.; Van Der Ende, A.; Grundmeijer, H. G. L. M.; Tytgat, G. N. J.; Van Der Hulst, R. W. M.

Ulcer-healing drugs are required after eradication of Helicobacter pylori in patients with gastric ulcer but not duodenal ulcer haemorrhage
pp. 1071-1076(6)
Authors: Lai, K. C.; Hui, W. M.; Wong, B. C. Y.; Hu, W. H. C.; Lam, S. K.

Pantoprazole versus one-week Helicobacter pylori eradication therapy for the prevention of acute NSAID-related gastroduodenal damage in elderly subjects
pp. 1077-1082(6)
Authors: Pilotto, A.; Di Mario, F.; Franceschi, M.; Leandro, G.; Battaglia, G.; Germanà, B.; Marin, R.; Valerio, G.

Rabeprazole, amoxycillin and low- or high-dose clarithromycin for cure of Helicobacter pylori infection
pp. 1083-1087(5)
Authors: Kihira, K.; Satoh, K.; Saifuku, K.; Kawakami, S.; Fukazawa, K.; Ishino, Y.; Kimura, K.; Sugano, K.

Cetraxate, a mucosal protective agent, combined with omeprazole, amoxycillin, and clarithromycin increases the eradication rate of Helicobacter pylori in smokers
pp. 1089-1094(6)
Authors: Kamada, T.; Haruma, K.; Miyoshi, E.; Mihara, M.; Kitadai, Y.; Yoshihara, M.; Sumii, K.; Kajiyama, G.; Tahara, K.; Mukai, T.; Kawamura, Y.; Hattori, N.

Nitric oxide formation in the dog sphincter of Oddi from nitric oxide donors as measured with in vivo micro-dialysis
pp. 1095-1101(7)
Authors: Yamamoto, I.; Fujimura, M.; Kihara, N.; Kumano, K.; Yamada, T.; Yamamoto, H.; Fujimiya, M.

Lifestyle measures and reflux
pp. 1103-1103(1)
Author: Kang, Jin-Yong

OAM for cure of Helicobacter pylori infection
pp. 1103-1104(2)
Authors: Savarino, V.; Mansi, C.; Vigneri, S.

Acid suppression and upper GI bleeding
pp. 1104-1105(2)
Authors: Netzer, P.; Inauen, W.

Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users
pp. 1105-1106(2)
Authors: Calvet, X.; Rue, M.

Reply —Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users
pp. 1106-1106(1)
Authors: Santolaria, S.; Lanas, A.